Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

I’m now very curious the strategy moving forward. Before the raise I thought it was simply to farm out RSV and focus on immunology. Now I’m not sure. The HR data gives high confidence for a successful phase 3 IMO but it’s going to take at least 2 years to enroll. So they might now be looking to co-develop amd want resources to opt into 323 w a partner as well. Of course this could just be leverage for a straight up outlicensing as well but the direction the company now takes is more up in the air I think